Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Denis Corbeil
Based on 1 article published since 2010
(Why 1 article?)
||||

Between 2010 and 2020, Denis Corbeil wrote the following article about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses. 2017

Sakai, Yasuhiro / Hong, Seung-Mo / An, Soyeon / Kim, Joo Young / Corbeil, Denis / Karbanová, Jana / Otani, Kyoko / Fujikura, Kohei / Song, Ki-Byung / Kim, Song Cheol / Akita, Masayuki / Nanno, Yoshihide / Toyama, Hirochika / Fukumoto, Takumi / Ku, Yonson / Hirose, Takanori / Itoh, Tomoo / Zen, Yoh. ·Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Electronic address: sakaiyasuhiro@gaia.eonet.ne.jp. · Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea. Electronic address: smhong28@gmail.com. · Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea. Electronic address: soyan21@gmail.com. · Department of Pathology, Korea University Anam Hospital, Korea University College of Medicine, Seoul 02841, Republic of Korea. Electronic address: lepetit80@hanmail.net. · Tissue Engineering Laboratories (BIOTEC), Technische Universität Dresden, Dresden 01307, Germany. Electronic address: denis.corbeil@biotec.tu-dresden.de. · Tissue Engineering Laboratories (BIOTEC), Technische Universität Dresden, Dresden 01307, Germany. Electronic address: jana.karbanova@biotec.tu-dresden.de. · Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Electronic address: otanikyo@med.kobe-u.ac.jp. · Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Electronic address: kofujikura@gmail.com. · Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea. Electronic address: mtsong21c@naver.com. · Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea. Electronic address: drksc@amc.seoul.kr. · Department of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Electronic address: bokuakkey70033@gmail.com. · Department of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Electronic address: yos_3n@hotmail.com. · Department of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Electronic address: tymhr@me.com. · Department of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Electronic address: fukumoto@med.kobe-u.ac.jp. · Department of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Electronic address: yonson@med.kobe-u.ac.jp. · Department of Pathology, Hyogo Cancer Center, Akashi 673-8558, Japan. Electronic address: thirose@hp.pref.hyogo.jp. · Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Electronic address: tomitoh@med.kobe-u.ac.jp. · Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Electronic address: yohzen@med.kobe-u.ac.jp. ·Hum Pathol · Pubmed #27864124.

ABSTRACT: The present study aimed to elucidate whether the stemness molecule, CD133, is expressed in well-differentiated pancreatic neuroendocrine tumors (PanNETs; World Health Organization grades 1 and 2) and establish its clinical relevance using 2 separate cohorts. In the first series (n = 178) in which tissue microarrays were available, immunohistochemistry revealed that CD133 was expressed in 14 cases (8%). CD133+ PanNETs had higher TNM stages (P < .01), more frequent lymphovascular invasion (P = .01), and higher recurrence rates (P = .01). In the second cohort (n = 56), the expression of CD133 and CK19 was examined in whole tissue sections. CD133 and CK19 were positive in 10 (18%) and 36 (64%) cases, respectively. CD133 expression correlated with higher pT scores (P < .01), the presence of microscopic venous infiltration (P = .03), and shorter disease-free periods (P < .01). When cases were divided into grade 1 and 2 neoplasms, patients with CD133+ PanNET continued to have shorter disease-free periods than did those with CD133- tumors in both groups (P < .01 and P = .02, respectively). Although CK19+ cases had shorter disease-free periods than did CK19- cases in the whole cohort (P = .02), this difference was less apparent in subanalyses of grade 1 and 2 cases. CD133 expression also appeared to be an independent predictive factor for tumor recurrence in a multivariate analysis (P = .018). The CD133 phenotype was identical between primary and metastatic foci in 17 of 18 cases from which tissues of metastatic deposits were available. In conclusion, the combination of CD133 phenotyping and World Health Organization grading may assist in stratifying patients in terms of the risk of progressive clinical courses.